Conversely, at current prices, GLP-1 RAs are unlikely to meet the arbitrary AU$28,000 per QALY willingness-to-pay threshold in either the total or secondary prevention population when considering only their benefits on CVD
Clues your aches may be GLP-1-related or medication adjacent: Aches begin or get worse after starting or increasing your GLP-1 dose Aches happen throughout your entire body rather than localized to a specific joint or muscle Youve also been experiencing nausea or reduced appetite Youre not drinking as much water as you used to You recently became more physically active Red flags that require prompt medical attention: Severe or worsening abdominal pain, especially radiating to the back (which could indicate possible pancreatitis) Dark-colored urine combined with muscle pain and weakness
The assays were conducted using kits from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and the absorbance was measured with a spectrophotometer
But a side effect quickly stole the spotlight: People taking GLP-1s started losing significant amounts of weight
Clinical trials show tirzepatide achieves 20-22% weight loss versus 14-17% for semaglutide, because tirzepatide activates both GLP-1 and GIP receptors simultaneously
through retesting
